정범선 (연세대학교 원주의과대학) | 한빛사논문 > 한빛사

한빛사논문

조회87

연세대학교 원주의과대학

Phytomedicine, May 21 2025, 143 S0944-7113(25)00527-6 | https://doi.org/10.1016/j.phymed.2025.156889 Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease

Tom Ryu ^a,#, Beom Sun Chung ^b,#, Jaejun Lee^c, Ji Won Han^c, Hyun Yang^c, Keungmo Yang ^c

^aDepartment of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, 04401, South Korea
^bDepartment of Anatomy, Yonsei University Wonju College of Medicine, Wonju, 26426, South Korea
^cDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, The Catholic University of Korea, Seoul, 06591, South Korea

^#Tom Ryu and Beom Sun Chung equally contributed to this work.
Corresponding author : Keungmo Yang

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern linked to increased risks of cardiovascular disease, chronic kidney disease (CKD), and premature mortality. Ginkgo biloba has shown potential therapeutic benefits in conditions characterized by metabolic dysfunction. This study aimed to evaluate the potential protective effects of Ginkgo biloba supplementation on overall survival (OS) and the incidence of cardiovascular and renal outcomes specifically in MASLD patients. This cohort study included 402,476 participants from the UK Biobank, categorized into MASLD and No steatotic liver disease (SLD) cohorts. Ginkgo biloba users and non-users were compared using inverse probability of treatment weighting to balance baseline characteristics. Clinical outcomes were assessed using Cox proportional hazards models, with subgroup analyses. Ginkgo biloba supplementation was associated with significantly improved OS [hazard ratio (HR) = 0.79, 95 % confidence interval (CI): 0.64-0.98, p = 0.034) and reduced risks of cardiovascular events (HR = 0.82, 95 % CI: 0.66-1.00, p = 0.012) and CKD (HR = 0.73, 95 % CI: 0.56-0.96, p = 0.012) in the MASLD cohort, while no significant benefits were observed in the No SLD cohort. Subgroup analyses indicated enhanced benefits in older adults, males, individuals with BMI ≥ 25 kg/m², and diabetic patients. The beneficial effects were pronounced in patients with advanced fibrosis. Ginkgo biloba supplementation is associated with improved survival and reduced cardiovascular and renal risks in MASLD patients, particularly in high-risk subgroups. These findings highlight the potential of Ginkgo biloba as an adjunctive therapy in MASLD management. This is the first large-scale study to examine the potential impact of Ginkgo biloba supplementation on clinical outcomes in MASLD, with fibrosis-stratified analyses providing insights into its differential effects across disease severity.

논문정보

형식Research article
게재일2025년 05월 (BRIC 등록일 2025-06-09)
연구진국내 연구진
분야 의약학 > 응용의학

댓글 작성 로그인

CV 열람하기

연락처 보기